Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening
Authors Nance K
Received 20 December 2012
Accepted for publication 20 December 2012
Published 21 January 2013 Volume 2013:5 Pages 1—3
Checked for plagiarism Yes
Keith V Nance
Medical Directory of Cytology, Rex Hospital, Raleigh, and Department of Pathology, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
I read with interest the recently published article by Naryshkin and Austin entitled "Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening".1 The article is a single case report of squamous cell carcinoma of the cervix diagnosed in a patient who had negative Hybrid Capture 2 (Qiagen NV, Hilden, Germany) high-risk human papillomavirus testing from SurePath™ (Becton-Dickinson, Franklin Lakes, NJ) samples. The authors then discuss several valid points regarding the use of human papillomavirus testing and cervical cancer screening not approved by the US Food and Drug Administration (FDA). Their conclusion is that such testing should not be done using the SurePath collection medium.
View the original paper by Naryshkin and Austin.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]